Switzerland
approves clinical trials
for Ebola vaccine
The public agency Swissmedic which
regulates pharmaceuticals in the country approved,
today November 6, the conducting of clinical trials
to test another experimental vaccine to combat the
Ebola virus, developed by the Canadian Public Health
Agency in a Geneva hospital, announced Bertrand
Levrat, the institution’s director, according to
Telesur.
The trials will be conducted with
120 healthy persons in the Swiss city of Lausanne’s
University Hospital. The plan is to inject 100 with
an inactivated virus protein, while the remaining 20
will receive a placebo.
Scientists expect results by mid-December,
depending on the recruitment of an adequate number
of volunteers.
